Showing results (91-100 of 117) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.JAMA|June 8, 2006
Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Brian I Rini, Ronald M Bukowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaRobert J Motzer, M Dror Michaelson, Bruce G Redman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancerM Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.Cancer Immunology Research|February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse EventsDylan J Martini, Lana Hamieh, Rana R McKay, et al.JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.European Journal of Cancer (Oxford, England : 1990)|November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failureNizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2023
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.Pageof 12